Appendix 4D and Half Year End Financial Report

**Emyria Limited Half-Year Financial Report Summary**

The half-year financial report for Emyria Limited ended 31 December 2024 shows a loss in revenues by 40% compared to the previous period, with a loss after tax of $968,997. The cash position at the end of the period was $1,551,069. Despite challenges, the financial statements are deemed to comply with accounting standards and provide a true and fair view.

Notable achievements during the period include securing bids in a strongly supported placement, receiving grants for drug development programs, and progressing therapy programs for PTSD and depression. The company also finalized an exclusive licensing agreement for serotonin-releasing agents.

Concerns about the company's ability to continue as a going concern are highlighted in Note 1 due to the loss incurred and uncertainties. To manage uncertainties, the company is exploring cost-saving measures and evaluating business opportunities to raise additional funds.

The Audit Director has declared independence and conducted a review of the financial statements confirming compliance with reporting requirements. They have not identified any concerns that would indicate non-compliance with regulations.

For further information or questions regarding the financial report, we welcome queries from current or prospective investors. Shareholders are encouraged to seek clarification on any aspects of the report to ensure transparency and understanding.

*Greg Hutchinson*

*Executive Chairman*

*Emyria Limited*

[Contact Information]

For detailed financial information, including statements of profit or loss, financial position, and cash flows, please refer to the full half-year financial report available on the company's website or through official channels.